First Eagle Investments, an investment management company, released its “First Eagle Global Fund” second-quarter 2025 ...

Becton Dickinson & Co. closed 24.10% short of its 52-week high of $251.99, which the company reached on February 3rd.

Investors need to pay close attention to Becton Dickinson stock based on the movements in the options market lately.

Becton, Dickinson and Company (NYSE:BDX) is a medical device company that develops and manufactures medical supplies, devices, laboratory equipment, and diagnostic products.

In addition, Becton, Dickinson, and Company (NYSE:BDX) is planning a $2.5 billion investment in the US as it looks to enhance its manufacturing capacity in response to the trade tariffs.

Becton Dickinson & Co. closed 21.41% short of its 52-week high of $251.99, which the company achieved on February 3rd.

Becton, Dickinson and Company (NYSE:BDX) reported revenue of $5.1 billion in Q1 2025, up nearly 10% from the same period last year. The revenue also beat analysts’ estimates by $59.6 million.

Becton, Dickinson and Company have underperformed the Dow Jones Industrials Average over the past year, yet Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Shares of Becton, Dickinson and Company (NYSE:BDX – Get Free Report) have been given a consensus rating of “Hold” by the eleven research firms that are currently covering the company ...

Becton, Dickinson And Company's major challenges, including the Alaris pump and Covid comparisons, are starting to normalize. Find out if BDX stock is a buy.

News about Becton Dickinson & Company, including commentary and archival articles published in The New York Times.